Brazilian red propolis exerts a cytotoxic action against prostate cancer cells and upregulates human monocyte functions

• Autor(a) principal: Santiago, Karina Basso [UNESP]
• Data de Publicação: 2022
• Outros Autores: Rodrigues, João Carlos Zamae [UNESP], de Oliveira Cardoso, Eliza [UNESP], Conte, Fernanda Lopes [UNESP], Tasca, Karen Ingrid [UNESP], Romagnoli, Graziela Gorete, Aldana-Mejía, Jennyfer Andrea, Bastos, Jairo Kenupp, Sforcin, José Maurício [UNESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1002/ptr.7618; http://hdl.handle.net/11449/242259
• topic: cytokine; immunomodulation; monocyte; propolis; prostate cancer; toll-like receptor

Different propolis samples can be obtained in Brazil, such as green, brown and red. Studies related to Brazilian red propolis (BRP) have increased in the last few years, so the aim of this study was to investigate its effects on the prostate cell lines LNCaP and PC-3 and on human monocytes. BRP chemical composition was analyzed by HPLC-DAD, the viability of monocyte and cancer cell by MTT assay. Cytokine production (TNF-α, IL-1β, IL-6, IL-10) by monocytes was quantitated by ELISA, the expression of cell markers (TLR-2, TLR-4, HLA-DR, CD80) and reactive oxygen species by flow cytometry. The candidacidal activity and the effects of supernatant of treated monocytes on tumor cells were assessed. BRP affected LNCaP viability after 48 and 72 h, while PC-3 cells were more resistant over time. BRP upregulated CD80 and HLA-DR expression, and stimulated TNF-α, IL-6 and IL-10 production. BRP enhanced the fungicidal activity of monocytes, displayed an antioxidant action and the supernatant of BRP-treated monocytes diminished LNCaP viability. In the search for new immunomodulatory and antitumoral agents, BRP exerted a selective cytotoxic activity on prostate cancer cells and an immunomodulatory action, suggesting its potential for clinical trials with oncological patients and for the discovery of new immunomodulatory and antitumor drugs.